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Pierre Lemaitre12, Michael Herfs13, Julien Chapuis14, Bart Ghesquiere15, Didier Vertommen16, 
Verena Kriechbaumer9, Kèvin Knoops17, Carmen Lopez-Iglesias17, Marc van Zandvoort18,  
Jean-Charles Lambert14, Julien Hanson19, Christophe Desmet12, Marc Thiry20,  
Kyle J. Lauersen21, Marc Vidal22,23, Pieter Van Vlierberghe10,11, Franck Dequiedt2*, 
Kourosh Salehi-Ashtiani3,4*, Jean-Claude Twizere1,5,22*†
The endoplasmic reticulum (ER) is a central eukaryotic organelle with a tubular network made of hairpin proteins 
linked by hydrolysis of guanosine triphosphate nucleotides. Among posttranslational modifications initiated at the 
ER level, glycosylation is the most common reaction. However, our understanding of the impact of glycosylation on 
the ER structure remains unclear. Here, we show that exostosin-1 (EXT1) glycosyltransferase, an enzyme involved in 
N-glycosylation, is a key regulator of ER morphology and dynamics. We have integrated multiomics and superres-
olution imaging to characterize the broad effect of EXT1 inactivation, including the ER shape-dynamics- function 
relationships in mammalian cells. We have observed that inactivating EXT1 induces cell enlargement and enhances 
metabolic switches such as protein secretion. In particular, suppressing EXT1 in mouse thymocytes causes develop-
mental dysfunctions associated with the ER network extension. Last, our data illuminate the physical and functional 
aspects of the ER proteome-glycome-lipidome structure axis, with implications in biotechnology and medicine.
INTRODUCTION
The endoplasmic reticulum (ER) is one of the largest organelles of 
eukaryotic cells (1). It facilitates communication with other intra-
cellular organelles through its connection to the nuclear envelope 
and regulates interactions with the external environment via the 
secretion of proteins, polysaccharides, and lipids (2).
The ER is involved in numerous cellular processes, from lipid 
turnover to protein secretion and glycosylation. Part of the meta-
bolic flexibility of the ER is mediated by its dynamic and adaptable 
shape (3). During normal cell homeostasis, the ER is a complex net-
work of tubules and flat matrices that are in continuous motion. 
These substructures form a three-dimensional, regularly shaped 
network, which derives its form from the lipid bilayer and different 
groups of membrane-associated proteins (4). High-curvature regions, 
such as ER tubules and edges of ER sheets, are built by the oligo-
merization of hydrophobic hairpin domain–containing reticulons 
(RTNs) and receptor expression–enhancing proteins (REEPs) (5, 6). 
Flat matrices are formed by atlastin (ATL) guanosine triphospha-
tase (GTPase)–ER membrane associations; these proteins dimerize 
in opposing layers to hold lipid bilayers in this conformation (7). 
The curvature of flat matrices is mediated by the luminal bridging 
cytoskeleton-linking membrane protein 63 (8).
It is currently believed that cooperation between ER shape and 
luminal dynamics dictates ER functions (9). ER sheets are the primary 
sites for translation, translocation, and folding of integral membrane- 
bound and secreted proteins, while ER tubules are thought to be 
involved in other ER functions such as lipid synthesis and interactions 
with other organelles (5, 10). Cells actively adapt their ER tubule/sheet 
balance and dynamics to coordinate its morphology and function, 
in accordance with cellular demands (11). However, the molecular 
mechanisms underlying overall maintenance and flexibility of the 
ER network remain poorly characterized.
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One of the key roles the ER plays for the cell is the secretion of ex-
tracellular products and glycosylation of proteins. Our understanding 
of the mechanisms of glycosylation is now advanced enough to engi-
neer cell lines to confer customized glyco motifs for biotechnological 
and medicinal applications. However, our understanding of how 
these motifs affect the intracellular dynamics of cellular homeostasis 
is limited. Glycosylation proceeds by the synthesis of glycans and 
attachment to the acceptor peptide, which is initiated in the ER and 
terminates in the Golgi apparatus (12). Glycosylation is well known 
to regulate the physical properties of different glycolipid and glyco-
protein biopolymers at the surface of mammalian cells by controlling 
plasma membrane and cell coat morphologies (13). The impact of 
intracellular ER membrane protein component glycosylation, their 
interactions with membranes, and their contributions to cellular dy-
namics is entirely unknown. While permanent interactions between 
membrane curvature proteins are sufficient to form the basic ER 
structure (9, 14), protein- protein interactions and posttranslational 
modifications may participate in its dynamic shaping. It is, there-
fore, essential to decipher how glycosylation affects ER dynamics with-
in the cell in addition to defining the sequential steps leading to final 
glycosylation species of extracellular proteins.
Synthesis of glycans and their attachment to proteins occurs by 
the sequential activities of glycosyltransferases and glycosidases that 
compete for activated glycans and overlapping substrates (12). Pro-
tein N-glycosylation occurs in the ER lumen and is catalyzed by the 
oligosaccharyltransferase (OST) complex, which is composed of eight 
proteins in metazoans [ribophorin, defender against cell death 1 
(DAD1), tumor suppressor candidate 3 (Tusc3), OST4, transmem-
brane protein 258 (TMEM258), OST48, and catalytic subunits STT3 
oligosaccharyltransferase complex catalytic subunit A (STT3A) and 
STT3B] (15). The final composition of oligosaccharide chains bound 
to glycoproteins depends not only on localization and abundance of 
these enzymes but also on the availability and heterogeneity of sugar 
substrates. Exostosin-1 (EXT1) is an ER-resident glycosyltransferase 
involved in the polymerization of heparan sulfate (HS) (16). HS mole-
cules are found in all animal tissues and play a key role in many biolog-
ical activities, including development and cancer. While investigating 
the role of EXT1 in thymocyte development and cancer, we found that 
reduction of the EXT1 protein results in global changes in cellular ho-
meostasis, including cell size, organelle shapes and interactions, and 
cellular metabolism. We show that reprogramming of glycan moieties 
by reduction of this regulator can profoundly change ER structure 
concurrent with global metabolic shifts in protein and membrane lipid 
synthesis in cells.
RESULTS
Developmental defects following EXT1 inactivation  
are mediated by its genetic interactions
In a systematic interactome study, we previously showed that EXT1, 
an ER-resident type II transmembrane glycosyltransferase, inter-
acts with Notch1, a type I transmembrane receptor that is frequently 
mutated in cancers (17). Notch1 is essential for the development of 
numerous cell types, including thymocytes (18,  19). We thus hy-
pothesized that EXT1 might play a physiological role in T cell devel-
opment, potentially associated with its glycosyltransferase function 
and ER residency (Fig. 1A). Because homozygous EXT1-null mice 
die at embryonic day 8.5 (20), we crossed EXT1F/F (21) mice with mice 
expressing the Cre recombinase under the control of lck proximal 
promoter (22) to specifically target EXT1 in early developing thy-
mocytes. We found that EXT1 inactivation affects the early stage of 
thymocyte development, with a significant accumulation of immature 
double-negative CD4−, CD8− cells (DN) (P < 0.01; Fig. 1, B and C). 
We also used a NotchF/F line (23) to generate a conditional knockout 
(k.o.) of Notch1 or both EXT1 and Notch1 genes simultaneously (fig. 
S1, A and B). As previously shown (19), Notch1 inactivation leads to 
the accumulation of DN, at a higher extend compared to EXT1 k.o. 
(P < 0.0001; Fig. 1, B and C). In both cases, Notch1 or EXT1 inac-
tivation affects the late stages of thymocyte developmental stages 






Fig. 1. Developmental defects following EXT1 inactivation are mediated by its 
genetic interactions. (A) Framework to study the role of ER-resident EXT1 in thy-
mocyte development. MT, mitochondria. (B) Representative fluorescence-activated 
cell sorting (FACS) plots showing the surface phenotype of CD4 and CD8 T cells in 
thymocytes. Cell percentages are shown in quadrants. (C) The absolute number of 
thymocytes (of 2,500,000 total events) showing the surface receptor expression of 
DN, single positive (SP) and double positive (DP) populations. n = 6 mice (lck-cre, 
Notch1F/F/lck-cre, EXT1F/F/lck-cre, and Notch1F/F/EXT1F/F/lck-cre). One-way ANOVA: 
**P < 0.01, ****P < 0.0001. (D) Representative FACS plots showing the surface 
expression of CD44 and CD25 markers in DN populations. Cell percentages are 
shown in quadrants. (E) The absolute number of DN1, DN2, DN3, and DN4 cells (of 
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thymic inactivation of both genes exhibit a normal phenotype, suggest-
ing a genetic suppression interaction between Notch1 and EXT1 in thy-
mocytes (Fig. 1, B to E). Because the altered phenotype in Notch1-deficient 
thymocytes was rescued by EXT1 k.o., we concluded that EXT1 may act 
as a functional suppressor partner of the Notch1 receptor in vivo.
Cancer dependency to EXT1 expression is associated 
with perturbations of ER structures
The unexpected phenotype generated by Notch1 and EXT1 double 
k.o. allowed us to hypothesize that EXT1 could be a candidate syn-
thetic lethal (SL) (24) or synthetic dosage lethal (SDL) (25) gene 
with activated oncogenic Notch1. To test the SDL hypothesis, we 
knocked down or overexpressed EXT1 in Jurkat (fig. S1, C and D), 
a T cell acute lymphoblastic leukemia (ALL) cell line, which has al-
tered Notch1 signaling (fig. S1, E and F). Dosage variations did not 
influence Jurkat cell proliferation (fig. S1G). However, when injected 
into nonobese diabetic/severe combined immunodeficient (NOD/
SCID) mice (26), we observed a notable and significant reduction in 
tumorigenicity following EXT1 knockdown (k.d.) (P < 0.0001; Fig. 2, 
A and B). Concurrently, overexpression of EXT1 was found to cause 
more tumor burden than control Jurkat T-ALL cells (Fig. 2, C and D), 
demonstrating a dosage lethality effect of EXT1 in the Jurkat T cell 
model. To test the SL hypothesis, we interrogated the gold standard 
SL gene pairs across different cancer types (24, 25). In these cancer 
patient cell lines, we did not observe any SL interaction between EXT1 
and Notch1, or EXT1 and the Notch1 ubiquitin ligase encoding gene 
FBXW7. However, EXT1 and Notch1 do synthetically interact with 
several shared genes, including important oncogenes: KRAS, PTEN, 
BRCAC2, and MYC (fig. S1H). EXT1 also appears as a clinically signif-
icant hub, for which down-regulation by short hairpin RNA (shRNA) 
presented numerous SL interactions relevant for various cancer types 
(fig. S1H). An exploration of The Cancer Genome Atlas (TCGA) for 
somatic mutations in different cancer cell lines and tumors also high-
lighted EXT1 as a clinically relevant hub (fig. S1, I and J). These findings 
suggest that EXT1 is a genetic suppressor of Notch1 and a potential 
precision therapeutic target in cancers for which Notch1 and other 
selected oncogenes are activated.
We next sought to investigate the molecular mechanisms under-
lying the identification of EXT1 as a suppressor hub. Because the EXT1 
protein localizes predominantly in the ER (27), we first assessed ER 
phenotypes of the thymus from mutant mice with inactivation of 
EXT1 (EXT1F/F/lck-cre) (Fig. 2E). We used immunohistochemistry 
to examine the expression of the ER-resident molecular chaperones 
Calnexin and protein disulfide isomerase family A member 3 (PDIA3) 
and observed a notable reduction in the expression of both markers 
in structural cells of the thymus from conditional EXT1 k.o. com-
pared to control mice (Fig. 2, F to H). To gain information about the 
consequences of EXT1 k.o. in the thymus, we analyzed mature lympho-
cytes migrating from the thymus. Transmission electron microscopy 
(TEM) analysis highlighted an unusual elongated ER morphology 
in activated CD4+ T cells from EXT1 k.o. mice (Fig. 2, I and J), with 
a concomitant increase in the T helper 1 interferon- (IFN-)–
producing cell population (Fig. 2K). The results suggest an import-
ant role of EXT1 in ER organization in T cells.
EXT1 down-regulation causes ER extension and cell 
size increase
The elongated morphology of ER in EXT1 k.o. mice thymocytes was 
unexpected. To rule out cell line–specific effects, we assessed the 
ultrastructural ER morphology in HeLa, human embryonic kidney 
(HEK) 293, and Jurkat cells. Following EXT1 k.d., we observed a 
dramatic elongation of ER tubules in all cell lines; for HeLa cell line, 
an average length of 109.6 ± 25.3 m is compared to 19.0 ± 8.0 m 
in control cells (Fig. 3, A and B, and fig. S2, A to E). The depletion 
of other members of the exostosin family (EXT2 and EXTL1-3) did 
not lead to similar ER changes (fig. S2, F to H). Probably as a conse-
quence of ER extension, the cell area increased by ~2-fold in EXT1 
k.d. cells compared to controls (133.9 ± 36.8 and 68.5 ± 12.5 m2, 
respectively) (Fig. 3, C and D). Cell size is of fundamental importance 
to all biological processes, and it is strictly regulated to keep a bal-
ance between growth and division. We did not observe any signifi-
cant effect on proliferation following EXT1 k.d. (fig. S3, A and B), 
suggesting that EXT1 k.d. cells might have undergone an important 
adaptive change of the size threshold following ER extension and 
internal cellular architecture rearrangement (Fig. 3, A and C).
To analyze the ER luminal structural rearrangements, we quanti-
fied ER membrane structures marked with SEC61 translocon subunit 
beta (SEC61b) by confocal microscopy and a segmentation algorithm 
that excludes insufficient fluorescent intensity. This strategy generates 
a single-pixel-wide network to allow the quantification of individual 
tubule morphological features. The tubular ER network was altered in 
EXT1 k.d. cells and exhibited a denser and more reticulated phenotype 
in comparison to controls (Fig. 3E). Measurements of the polygonal 
area of the ER tubular network in these cells were 0.778 m2, which is 
a reduction from 0.946 m2 in controls (Fig. 3F). Other tubular and 
cisternal ER metrics were unaffected (fig. S3, C to E), suggesting that 
the dense tubular network might relate to a more crowded ER lumen.
We next analyzed ER interactions with other organelles and counted 
significantly more peripheral ER–nuclear envelope (2.3 ± 1.2 versus 
0.6 ± 0.9) and less ER-mitochondria (21.6 ± 10.2 versus 35.4 ± 9.3) 
interactions in HeLa EXT1 k.d. compared to control cells (Fig. 3, 
G to J). The latter was unexpected given the ~5.7-fold increase in ER 
length (Fig.  3B). However, it was found to correlate with an im-
paired calcium flux in those cells (fig. S3, F and G), suggesting that 
cells undergo a metabolic switch following EXT1 k.d.
EXT1 reduction induces Golgi reorganization 
and a metabolic switch
Although EXT1 is an ER-resident protein, it is also found in the Golgi 
apparatus, where it forms a catalytic heterodimer enzyme that po-
lymerizes the elongation of HS chains by sequential addition of glu-
curonic acid and N-acetylglucosamine (GlcNAc) (28). In addition 
to the notable changes in ER structure, TEM ultrastructural exam-
ination of EXT1 k.d. cells revealed structural changes in the Golgi 
apparatus size and shape (Fig. 4A). The number of Golgi cisternae per 
stack was reduced (3.0 ± 0.9 in EXT1 k.d. compared to 3.8 ± 1.0 in 
control cells; Fig. 4B), and stacks were dilated and shorter in length 
(729.2 ± 329.0 in EXT1 k.d. compared to 1036.0 ± 312.0 nm in con-
trol cells; Fig. 4C). Modified Golgi morphology combined with the 
reduction in ER-mitochondria interactions points toward global 
metabolic changes in EXT1 k.d. cells.
To assess the implications of EXT1 in cellular metabolism, we used 
two different strategies. First, we generated transcriptomic data (17) 
from cells treated with EXT1 small interfering RNA (siRNA) and 
control cells to reconstruct two in silico flux balance analysis (FBA) 
models using constraint-based reconstruction analysis (COBRA) 
(29) tools and the human RECON2 metabolic model (29). We found, 
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Fig. 2. Cancer dependency to EXT1 expression is associated with perturbations of ER structures. (A and B) Follow-up of the tumor progression via bioluminescence 
after injection of 2 × 106 control and shEXT1 Jurkat cells at opposites sites of NOD/SCID mice. a.u., arbitrary units. ****P < 0.0001. (C and D) As in (A) and (B) for CTRL–GFP 
(green fluorescent protein) and EXT1-GFP cells. One-way analysis of variance (ANOVA), *P < 0.05, **P < 0.01, and ****P < 0.0001 (n = 6 to 10 mice per group). (E) Immuno-
histochemistry staining of EXT1 protein in thymus of lck-cre (left) and EXT1F/F/lck-cre (right) mice. Scale bars, 2 m. (F) As in (E) but immunohistochemistry staining with 
anti-Calnexin antibody. Scale bars, 2 m. (G) As in (E) but immunohistochemistry staining with anti–protein disulfide isomerase family A member 3 (PDIA3) antibody. Scale 
bars, 2 m. (H) Quantifications of NanoZoomer Digital Pathology Image (ndpi) slide scans using QuPath 0.2.0-m8. Positive cells per square millimeter from indicated 
conditions are plotted. One-way ANOVA, **P < 0.01 and ****P < 0.0001 (n = 4 scan area per staining, five mice per group). (I) TEM of ER in activated T cells from murine pe-
ripheral lymph nodes and spleen. Scale bars, 2 m. Boxed region illustrates the ER. (J) Quantification of the length of tubular ER. One-way ANOVA, ***P < 0.001 (n = 25 cells, 
6 to 10 mice per group). (K) The percentages of interferon- (IFN-) in T helper 1 cell (TH1) from lck-cre and EXT1F/F/lck-cre mice are shown in quadrants. Percentages of 
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control models when the production of biomass was optimized (fig. 
S4A). These reactions are involved in the tricarboxylic acid (TCA) 
cycle, glycerophospholipid metabolism, pyruvate, methane, and sphin-
golipid metabolism (fig. S4B). Second, we performed a high-throughput 
metabolomic analysis of the relative abundance and fractional contri-
bution of intracellular metabolites from major metabolic pathways in 
living EXT1 k.d. compared to control cells. We did not observe sig-







Fig. 3. EXT1 down-regulation causes ER extension and cell size increase. (A) TEM of the ultrastructure ER of HeLa cells. Scale bars, 2 m. (B) Quantification of the length of tu-
bular ER (in nanometers) per cell (n = 10 cells, three independent experiments). Box plot indicates that the mean and whiskers show the minimum and maximum values. One-way 
ANOVA, ****P < 0.0001. (C) TEM of HeLa shCTRL and shEXT1 cells. Scale bars, 2 m. (D) Quantification of the cell area (n = 19 to 22 cells, three independent experiments; table S1). 
One-way ANOVA, ****P < 0.0001. (E) Confocal fluorescence of Cos7 cells shCTRL or shEXT1 transiently expressing mEmerald-Sec61b. From top to bottom: original image, skeleton, 
overlay of the skeleton (purple), the cisternae (white) and the original image (green), polygonal regions map, and color-coded by size. (F) Quantitative analysis based on the skele-
tonization model of Cos7 cells expressing mEmerald-Sec61b under shCTRL and shEXT1 condition. Polygon area (log10) in x axis is plotted against scaled density in y axis 
(n = 19 to 24). (G) TEM of ER-mitochondria and ER–nuclear envelope contact sites in HeLa shCTRL and shEXT1 cells. Arrows in blue and red highlight the contact sites. The nuclear 
envelope–ER contact sites increase and the number of mitochondria-ER contact sites decreases following EXT1 depletion. Scale bars, 500 nm. (H) Schematic representation of the 
ER–other organelle contact sites, as used for the statistical analysis of the different parameters. (I) Quantification of the ER–nuclear envelope contact sites in box plot indi-
cating that the mean and whiskers show the minimum and maximum values (n = 10 to 18 cells, three independent experiments). One-way ANOVA, ****P < 0.0001. (J) As 
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However, in agreement with our in silico FBA, we found that several 
nucleotides, amino acids, and metabolites from the TCA cycle were 
dysregulated in EXT1 k.d. cells (Fig. 4, D to H, and fig. S4, C to E).
The fractional contribution of glucose carbons into these pools 
of metabolites was also decreased in EXT1 k.d. cells (Fig. 4, E and F). For 
instance, the fractional contributions of citric acid (change, 12.51%; 
P < 0.001), -ketoglutarate (change, 13.87%; P < 0.0001), fumarate 
(change, 11.61%; P < 0.001), malate (change, 13.74%; P < 0.0001), 
and oxaloacetate (change, 15.97%; P < 0.0001) were significantly 
reduced in EXT1 k.d. cells (Fig. 4F). Isotopologue profile analysis 
of TCA intermediates suggested that mitochondria were in a less 
oxidative mode of action in EXT1 k.d. cells, as m03, m04, m05, and 
m06 of citric acid were much lower in abundance (Fig. 4G and fig. 
S4E). In contrast, metabolite pools of the pentose phosphate path-
way, the m05 of different nucleotides [adenosine triphosphate (ATP), 
uridine triphosphate (UTP), guanosine triphosphate (GTP), and 
cytidine triphosphate (CTP)], and the energy charge were increased 
in the EXT1 k.d. cells (Fig. 4H and fig. S4, F and G). Together, these 
findings indicate a higher de novo synthesis and consumption rate 
of nucleotides necessary for the synthesis of sugar intermediates used 
in protein glycosylation [i.e., uridine diphosphate (UDP)–GlcNAc] 







Fig. 4. EXT1 reduction induces Golgi reorganization and a metabolic switch. (A) TEM of Golgi apparatus in HeLa shCTRL and shEXT1 cells. Silencing EXT1 results in 
reduced number and increased size of Golgi cisternae/stacks. Scale bars, 500 nm. (B and C) The number of Golgi cisternae/stacks (B) and maximum length of individual 
Golgi cisternae (in nanometers) (C) were quantified on the basis of TEM images (n = 20; table S1). One-way ANOVA, ****P < 0.0001. (D) Scatterplot of raw cell abundance 
profile of metabolites. (E) Heatmap z score represents fractional labeling of metabolites. Metabolites were clustered using one-minus Spearman’s rank correlation. 
PCC, Pearson’s Correlation Coefficient. (F) Fractional contribution from 13C6-glucose to TCA metabolites (n = 3). One-way ANOVA, ****P < 0.0001. AKG, -ketoglutarate. 
(G) Isotopomer distribution of citrate derivatives into the TCA cycle in HEK293 cells (n = 3). (H) Cell abundance of nucleotides showing altered energy balance shift. 
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EXT1 k.d. causes changes in the molecular composition 
of ER membranes
To understand the molecular mechanisms of the EXT1-mediated 
cellular metabolic changes observed above, we isolated the ER micro-
somes from EXT1 k.d. and control cells. TEM revealed that, in the 
absence of EXT1, the structure of ER membranes was modified, as 
vesicle-like fragments were observed compared to the normal het-
erogeneous microsomes in control cells (Fig. 5A).
On the basis of this observation, we comprehensively compared the 
glycome, proteome, and lipidome profiles of those ER membranes in con-
trol and EXT1 k.d. cells. Glycome analysis using matrix-assisted laser 
desorption/ionization–time-of-flight mass spectrometry (MALDI- TOF 
MS) enabled absolute and relative quantification of glycoprotein N- 
and O-glycan abundances, respectively, in these cell lines. The k.d. of 
EXT1 did not induce the appearance of new glycan species on mem-
brane proteins (fig. S5A). However, we observed a significant shift 
A C D
B G
E H I J
F
Fig. 5. EXT1 k.d. causes changes in the molecular composition of ER membranes. (A) TEM of ER microsomes isolated from HeLa cells. Scale bars, 1 m. (B) Glycomic 
analysis of microsomes. Relative abundance of each N-glycan in shEXT1 versus shCTRL microsomes. The variations are plotted by N-glycan mass. (C) As in (B), the bars 
indicate the fold change of the total O- and N-glycan intensities. (D) Expression of OST complex subunits (STT3a, STT3b, and Dad1), other translocon members (Sec62, 
Sec63, and Trap-), and ER constitutive markers Calnexin and RTN4 in microsomes. (E and F) Schematic representation of the OST complex for which catalytic subunits 
STT3A and STT3B are less glycosylated following EXT1 k.d. MAGT1, magnesium transporter 1. (G) Quantitative proteomic analysis of microsomes. Pie chart illustrates the 
number of up-regulated and down-regulated proteins. (H) Heatmap to quantify 23 ER integral proteins. ASPH, aspartate beta-hydroxylase; CHERP, calcium homeostasis 
endoplasmic reticulum protein; CKAP4, cytoskeleton associated protein 4; COPB1, COPI coat complex subunit beta 1; DDOST, dolichyl-diphosphooligosaccharide–protein 
glycosyltransferase non-catalytic subunit; ERMP1, endoplasmic reticulum metallopeptidase 1; GALNT2, polypeptide N-acetylgalactosaminyltransferase 2; GOLM1, Golgi 
membrane protein 1; ITPR3, inositol 1,4,5-trisphosphate receptor type 3; LARS, leucyl-TRNA synthetase 1; ERGIC/P53, endoplasmic reticulum-Golgi intermediate compartment 
53 KDa protein; LPCAT1, lysophosphatidylcholine acyltransferase 1; NCLN, nicalin; PIEZO1, piezo type mechanosensitive ion channel component 1; PLAUR, plasminogen 
activator, urokinase receptor; RPLPO, 60S acidic ribosomal protein PO; RPS23, ribosomal protein S23; TMBIM6, transmembrane BAX inhibitor motif containing 6; TMEM43, 
transmembrane protein 43; VCP, valosin containing protein; ZMPSTE24, zinc metallopeptidase STE24. (I) Lipidomic analysis of different lipid species as found in microsomes. 
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toward higher–molecular weight N-glycans and more O-glycosylation 
compared to control ER membranes (Fig. 5, B and C). The total relative 
amount of N-glycans was reduced, consistent with the lower cellular 
abundance of UDP-GlcNAc (Fig. 5C and fig. S5B). This deregulation 
appears to occur, at least in part, at the level of the first step during 
protein N-glycosylation, which involves the OST complex. Microsomes 
isolated from EXT1 k.d. cells had reduced amounts of OST complex 
proteins STT3A, STT3B, and Dad1 (Fig. 5D).
N-glycosylation in eukaryotes is cotranslational (30). In agreement 
with the finding that EXT1 k.d. impairs N-glycosylation, we observed 
that some members of the translocon complex (Sec62 and Sec63), the 
translocon-associated protein complex (TRAP), and the N-glycosylation 
quality control protein Calnexin were found to be reduced in EXT1 
k.d. cells compared to controls (Fig. 5D). Using a tandem MS (MS/MS) 
analysis followed by glycopeptide identification, we found that EXT1 
k.d. specifically reduced the N-glycosylation of asparagine (N) residues 
N548 and N627 in STT3A and STT3B, respectively, which are the cata-
lytic subunits of the OST complex (Fig. 5, E and F). Although the role of 
N-glycosylation of human STT3A and STT3B is still unknown, in yeast, 
N-glycosylation of the ortholog Stt3 mediates the assembly of the OST 
subcomplexes via interaction with wheat germ agglutinin-binding pro-
tein (Wbp1) and suppressor of a Wbp1 mutation (Swp1) (31).
MS/MS proteomic analysis also identified 226 proteins that were 
differentially abundant in ER membranes of EXT1 k.d. cells, includ-
ing 23 ER-resident proteins. Specifically, RTN4 and ATL3 ER-shaping 
proteins were found in lower abundance in EXT1 k.d. cells (Fig. 5, 
G and H). However, valosin-containing protein (VCP), an adenosine 
triphosphatase involved in lipid recruitment during ER formation, and 
a glycan-binding component of the ER-Golgi intermediate compart-
ment that is involved in ER reorganization, ERGIC/p53, were in high-
er abundance (Fig. 5H). Consistent with the increase in O-glycans 
(Fig. 5B), ER membranes from EXT1 k.d. cells were also found to have 
higher amounts of N-acetylgalactosamine transferase 2 (GALNT2) 
(Fig. 5H) and an overall higher glycosyltransferase activity in ER micro-
somes (fig. S5C). These results confirm that the ER proteome, including 
shaping proteins and ER enzymes, is deregulated following EXT1 k.d.
Examination of lipid classes in ER microsomes also highlighted 
significant changes following EXT1 depletion (Fig. 5, I and J). The most 
significant increase was observed in cholesterol esters (CEs), which 
were ~9-fold higher in EXT1 k.d. membranes compared to control 
(Fig. 5, I and J). Changes were also observed in phospholipids such as 
phosphatidylcholine (PC), phosphatidylserine (PS), and sphingomyelin 
(SM) (Fig. 5, I and J). We concluded that, in the absence of EXT1, ER 
membrane lipid composition is modified toward structural fluidity.
EXT1 localizes in ER tubules and sheet matrices
The above results suggest a role of EXT1 in the maintenance of the 
ER structure. Previous studies have shown that EXT1 localizes pre-
dominantly to the ER (16). However, whether EXT1 localizes in the 
ER tubules or sheet matrices was not investigated because of the spa-
tial limitations of optical microscopy. To precisely characterize EXT1 
localization in ER structures, we performed superresolution (SR) im-
aging with EXT1 tagged with strongly enhanced yellow fluorescent 
protein 2 (SYFP2) and mEmerald, two fluorophores with different 
photostability properties. Using two SR technologies, stimulated emis-
sion depletion (STED) and structured illumination microscopy (SIM), 
we found that EXT1 localized in dense sheets and peripheral ER tu-
bules (Fig. 6, A and B, and fig. S6A). EXT1 largely colocalized with 
the ER luminal marker PDIA3 (Fig. 6C) and, to lesser extent, with 
lectin chaperone Calnexin and Golgi marker GM130 (fig. S6, B to D). 
EXT1 perfectly colocalized with ER-shaping proteins Lunapark1 
(Lnp1), ATL1, and RTN4a in tubules and the ER three-way junc-
tions (Fig. 6, D to F, and fig. S6D).
To assess whether EXT1 k.d. might affect ER luminal dynamics, 
we analyzed the dynamic motion of ER tubules and three-way junc-
tions by tracking the trajectories of ATL1 and Lnp1 proteins using 
live imaging (movies S1 to S4). In validated Cos7 EXT1 k.d. cells 
(fig. S6E), the ER periphery morphology is asymmetrically dispersed 
compared to controls cells. While Lnp1 and ATL1 markers showed 
significant increase in the tubular ER polygon area (fig. S6F), RTN4a 
showed increased membranous localization following EXT1 k.d. 
(Fig. 6G). We quantified the ratio between the ER tubules and three-
way junctions, which indicated that the ER fusion rate was not affected 
following k.d. of EXT1 (fig. S6G). Next, we adapted a previously de-
scribed single-molecule localization algorithm (32) to reconstruct the 
diffusivity and velocities at the three-way junctions (fig. S6, H to J). We 
computed particle distributions, trajectories, and velocities and found 
ATL1 to have a higher diffusivity and instantaneous velocity than Lnp1 
(fig. S6, H to J), consistent with their respective localizations in the ER 
tubules and three-way junctions. The maximum tubular motion ob-
served here (velocity of ~3 m/s) was lower than the luminal motion in 
previous observations (10 to 40 m/s) (fig. S6K) (32). EXT1 reduction 
by k.d. did not affect tubule motion, suggesting that the ER morpholo-
gy changes in EXT1 k.d. cells might result from luminal flow changes, 
potentially driven by intracellular redistribution of HS (Fig. 6H).
The molecular chaperone Calnexin, which assists protein folding 
in the ER, exhibited an aggregation pattern in EXT1 k.d. cells (Fig. 6I 
and fig. S6N), which might result in decreased movement of mole-
cules through the ER lumen. To assess how a reduced polygonal 
area following EXT1 k.d. might influence ER luminal protein mobil-
ity and network continuity, we quantified the relative diffusion and 
active transport through the lumen of an ER lumen marker PA–GFP–
KDEL (photoactivable–green fluorescent protein–lysine-aspartic acid- 
glutamic acid-leucine). Its signal was spread throughout the entire 
ER network, demonstrating that the continuity of ER was not affected 
in EXT1 k.d. cells (movies S5 and S6). However, we observed a sig-
nificantly higher dynamic of fluorescence intensity in regions close 
to the nucleus (fig. S6, L and M, at 8, 12, and 16 m), suggesting that 
the structural rearrangements of the ER following EXT1 k.d. actively 
participate in luminal protein transport. Together, these data demon-
strate that EXT1 k.d. induces ER morphological changes that impair 
protein movement through the ER.
EXT1 k.d. results in increased secretory cargo trafficking
To comprehensively assess the function of EXT1 in protein dynam-
ics through the ER, we combined interactome analysis with imaging 
approaches. First, we captured the EXT1 interactome in the ER mi-
crosomes by affinity purification and MS analysis (table S6). Consist-
ent with a role in the ER morphology, spatial analysis of functional 
enrichment (SAFE) was used to identify three functional modules 
within EXT1 interactors, two of which were translation initiation and 
protein targeting to the ER (Fig. 7A). Next, we investigated the poten-
tial connections between EXT1 and the secretory pathway by compar-
ing the proteome isolated from control and EXT1 k.d. cells after stable 
isotope labeling by amino acids (SILAC) (Fig. 7B). Differential protein 
expression analysis indicated the up-regulation of COPII anterograde 
vesicle-mediated transport components, with concomitant down- 
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(Fig. 7, C and D). Thus, we hypothesized that the depletion of EXT1 led 
to the enhancement of protein recruitment into the luminal ER and 
subsequent secretion or distribution into cellular membranes.
To further assess the changes in the secretory pathway, we moni-
tored anterograde transport using the retention selective hook (RUSH) 
system (33) that enables the synchronization of cargo trafficking. By 
tracking cargo transport from the ER to the Golgi using live imag-
ing, we observed a slower dynamic response in EXT1 k.d. cells that 
resulted in an increased residency of the cargo within the secretory 
pathway (Fig. 7, E and F, and movies S7 and S8). This finding was con-
firmed using an additional ER export assay based on the vesicular 
stomatitis virus glycoprotein (VSVG) (fig. S7, A and B) and by exam-
ining COPII coat structural components SEC16 and SEC31 (fig. S7, C 
and D). TEM analysis also indicated a higher number of trans-Golgi 
secretory vesicles (11.83 ± 7 and 2.4 ± 1.6 secretion vesicles per cell 









Fig. 6. EXT1 localizes in ER tubules and sheet matrices. (A and B) STED (A) and SIM (B) images of Cos7 cells expressing SYFP2-EXT1 and mEmerald-EXT1, respectively. 
Boxed regions illustrate the tubular (subpanel a) and the cisternal (subpanel b) ER. Scale bars, 4 m. (C) Confocal fluorescence microscopy of Cos7 cells transiently expressing 
SYFP2-EXT1 (green) and endogenous ER marker PDIA3 (red). The subpanels show the individual and merged channels and the colocalized pixel map (CPM). Scale bar, 4 m. 
(D to F) As in (C) but coexpression of SYFP2-EXT1 (green) and indicated ER markers (red). Scale bars, 4 μm. (G) Live imaging of shCTRL and shEXT1 Cos7 cells stably expressing 
indicated ER markers. Scale bars, 4 m. Boxed region illustrates the ER. (H) HS endogenous staining (red) of Cos7 cells. Scale bars, 5 m. (I) Endogenous staining (red) of Cos7 
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of EXT1 in HeLa cells (fig. S7, E and F). Last, we confirmed enhanced 
secretion by producing significantly more recombinant proteins 
(nanoluciferase) in HeLa EXT1 k.d. compared to control cells (fig. S7G). 
The integration of all the above results allowed us to conclude that 
EXT1 controls secretion by interacting with components of the gen-
eral translational initiation machinery (Fig. 7A). Thus, EXT1 expres-
sion reduction, as modeled by SAFE analysis combining quantitative 
transcriptional and translational expression (fig. S7H), affects sev-
eral processes in mammalian cell physiology and metabolism.
DISCUSSION
Multiple pieces of evidence indicate that EXT1 is broadly implicated 
in cancer, as suggested by the findings shared in the Cancer Cell Line 
Encyclopedia, TCGA, and Catalogue of Somatic Mutations in Cancer 
(34–36). EXT1 mutations range from 1% in small cell lung cancer 
tumors to 27% in colorectal cancers (fig. S1, I and J). At the protein level, 
we previously reported that EXT1 interacts with Notch1 (17). Here, 
we provide data showing that EXT1 gene should be considered as an 
additional regulator molecule involved in T lymphocyte development 
in mice (Fig. 1, B to E). Furthermore, our results from EXT1 and 
Notch1 double k.o. in developing thymocytes demonstrate that cells 
are able to pass the critical - and -selection checkpoints in the ab-
sence of Notch1 expression (Fig. 1, D and E). This genetic suppression 
interaction between EXT1 and Notch1 in developing thymocytes 
reflects a mechanism (exocytosis) potentially controlling T lineage 
specification, in addition to the well-known transcription and 
ligand-receptor modulations. Genetic suppression is one of the most 
powerful tools in yeast (37) and Caenorhabditis elegans (38) genetics. 
In these organisms, genetic suppression is facilitated by the ability to 
generate and handle a large number of individual mutations in vivo, 
allowing global-scale connection of genes involved in the same path-
way or biological process. Although systematic examination of EXT1 
genetic interactions was impractical in our mouse models, we demon-
strated an overlapping role of EXT1 and Notch1 in the developmen-
tal stages (DN3 and DN4) of thymocytes and an unexpected healthy 
phenotype of thymocytes with EXT1F/F Notch1F/F double k.o. We thus 
validated a physiological genetic suppression role of EXT1 in the 
function of the Notch1 transmembrane receptor. To further demon-
strate a potential global role of EXT1 in cancer, we took advantage 
of the SL (24) and the SDL (25) principles, whereby, for each pair, 
individual gene inactivation (SL) or expression variation (SDL) re-
sult in viable phenotypes, whereas combined perturbations are lethal. 
These approaches identified several oncogenes, including KRAS, 
CREBBP, PTEN, and BRCA2, as SDL genetic partners of EXT1, high-
lighting its potential clinical relevance in different cancers.
In vitro the formation of the ER tubular network requires only a 
small set of membrane curvature and stabilizing proteins (RTNs, 
REEPs, and large ATL GTPases) (14). However, these effectors can-
not account for the diversity and adaptability of ER size and mor-
phology observed in individual cell types. It is expected that in vivo, 
the dynamics of tubular three-way junctions and tubule rearrange-
ments to accommodate luminal flow mobility rely on additional 
proteins or mechanisms. Despite the discovery of glycoproteins in 
intracellular compartments 30 years ago (39), our knowledge about 
the glycoproteome is still biased toward secreted and plasma mem-
brane proteins. Glycosylation is well known to regulate the physical 
properties of different glycolipid and glycoprotein biopolymers at 
the surface of mammalian cells by controlling plasma membrane and 
cell coat morphologies (13). The central enzyme in the N-glycosylation 
pathway is the OST complex, which catalyzes the transfer of oligo-
saccharides from dolichol pyrophosphate–linked oligosaccharide 
to the nascent polypeptides in the protein translocon systems (40). 
The spatial organization of these protein modules is tightly regulated 
to coordinate temporally coupled synthesis, N-glycosylation, and pro-
tein translocation (41). The atomic structure of yeast OST complex 
highlighted a potential role of an N-glycan at the N539 position of the 
catalytic subunit STT3 in the stability of the OST complex by stick-
ing together Wbp1 and Swp1–interacting subunits (31). Here, we ob-
served that glycosylation of the corresponding residues N548 and 
N627 of STT3A and STT3B mammalian OST is impaired following the 
reduction of EXT1. This suggests that EXT1 is involved in the sta-
bility of the OST complex in the ER lumen, providing a mechanistic 






Fig. 7. EXT1 k.d. results in increased secretory cargo trafficking. (A) SAFE anal-
ysis of EXT1 interactome in ER microsomes. (B) Schematic representation of the 
SILAC workflow. (C and D) Up-regulated (C) and down-regulated (D) proteins in-
volved in anterograde and retrograde transport. (C) CAMSAP2, calmodulin regulated 
spectrin associated protein family member 2; CLIP1, CAP-gly domain-containing 
linker protein 1; KIF23, kinesin family member 23; SCFD2, Sec1 family domain con-
taining 2. (D) DNAH2, dynein axonemal heavy chain 2; DNMBP, dynamin binding 
protein; DYNC1LI2, dynein cytoplasmic 1 light intermediate chain 2; DYNLT3, dynein 
light chain tctex-type 3; GORASP1, Golgi reassembly stacking protein 1; MAP1A, 
microtubule associated protein 1A; MAP7D1, MAP7 domain containing 1; MYO1C, 
myosin IC; STX8, syntaxin 8. One-way ANOVA, *P < 0.05, ***P < 0.001, ****P < 0.0001. 
(E) Live imaging of retention selective hook (RUSH)–synchronized traffic of tumor 
necrosis factor (TNF) protein in HeLa cells. Scale bars, 10 m. (F) Mean normalized 
fluorescence intensity (a.u.) after the addition of biotin. Two-stage linear step-up 
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(Fig. 5C). The resulting alternative glycosylation pattern of ER mem-
brane proteins observed here correlated with extensive ER architec-
tural and functional remodeling. Our results suggest that EXT1 is 
topologically involved in the stability of the OST and the translocon 
complexes in the ER. Furthermore, the EXT1 interactome revealed 
here (Fig. 7 and table S6) contains the eucaryotic translation initia-
tion factor 3 (EIF3) subunits E, F, and I; elongation factor 1 (EEF1) 
1, 2, and  subunits; and several 40S and 60S ribosomal proteins 
(table S6). A compelling hypothesis following our observations is the pos-
sibility that EXT1 coordinates the stability of cotranslationally and 
posttranslationally N-glycosylated proteins in the ER. A potential link 
between the translasome and efficient protein synthesis and degrada-
tion in fission yeast was raised by Sha et al. (42). However, knowledge 
of the spatially organization of this supercomplex in mammalian cells is 
lacking and will require structural studies by cryo–electron micros-
copy to precisely locate EXT1 relatively to the EIF3-ribosome-EEF1.
The results presented here provide insights into a specific funda-
mental downstream role of EXT1 in the architecture of the ER. We 
demonstrated that the reduction of EXT1 affects ER structures, mem-
brane glycome, and lipid compositions, which have broad-ranging 
metabolic consequences for the cell. We hypothesize that the regu-
lation of ER-membrane macromolecular composition, via alterna-
tive glycosylation, reprograms ER trafficking and shape extension, 
which should enhance cellular productivity, as shown in fig. S7 (E to 
G). Thus, reprogramming N-glycosylation in the ER will have im-
plications in biotechnology including the production of recombi-
nant proteins, therapeutic viral vectors, and vaccines in mammalian 
cells. As exemplified by the current coronavirus disease 2019 pan-
demic, insufficient mammalian cell production capacity is a limita-
tion in their industrial use (43). EXT1 expression reduction, which 
affects the structure of the ER, also favors membrane structural fluidity 
and affects its luminal dynamics. Thus, our findings have demon-
strated that glycosylation is an important posttranslational modifi-
cation controlling the internal plasticity and structure function of 
the ER. In the future, it will be interesting to identify other glycosyl-
transferase enzymes that coregulate intracellular organelle morphol-
ogies. It is also essential to determine the atomic structure of EXT1 
at the ER to clarify the positioning of EXT1 relative to the OST, trans-
locon, and translasome complexes. Together, our findings suggest 
that the diversity of proteoglycans destined to the cell surface results 
from the glycosylation equilibrium of intracellular and plasma mem-
brane proteins. At the fundamental level, our findings argue for a 
general biophysical model of ER membrane extension and functions 
regulated by resident glycosyltransferase enzymes such as EXT1.
MATERIALS AND METHODS
Mice generation
T cell–specific deletion of EXT1, Notch1, or both genes on a C57BL/6J 
background was accomplished by intercrossing the EXT1 flox allele 
(21) or Notch1 allele (23) and the lck-cre transgene (22). EXT1 flox/
flox and Notch1 flox/flox mice were a gift from Y. Yamaguchi (Sanford 
Children’s Health Research Center, Sanford-Burnham Medical Re-
search Institute, La Jolla, CA, USA) and F. Radtke (Ecole Polytech-
nique Federale de Lausanne, Lausanne, Switzerland), respectively. 
LCK-CRE [4-8, B6.Cg-Tg (Lck-cre) 548Jxm/J] mice were purchased 
from the Jackson laboratory. T cell–specific depletion of EXT1 and 
Notch1 were verified by polymerase chain reaction (PCR). To detect 
the deletion of the EXT1 gene by PCR, the following primers were 
used on tail tips: BURN-51, 5′-GGAGTGTGGATGAGTTGAAG-3′; 
BURN-52, 5′-CAACACTTTCAGCTCCAGTC-3′; and BURN-35, 
5′-CCAAAACTTGGATACGAGCC-3′. BURN-51 and BURN-52 
generate a 460–base pair (bp) fragment from the wild-type allele, and 
BURN-51 and BURN-35 generate a 509-bp fragment from a CRE-excised 
allele. To detect Notch1 deletion by PCR, we used the following primers, 
generating a 500-bp floxed fragment and 450 bp in wild type: 204 N1 
new S, 5′-CTGAGGCCTAGAGCCTTGAA-3′; 205 N1 new AS, 
5′-TGTGGGACCCAGAAGTTAGG-3′. We also used the following 
primers, detecting a deleted band at 400 bp: 15 N1 5′lox, 5′-CTGACT-
TAGTAG GGGGAAAAC-3′; 17 N1 del3, 5′-AATCAGAGCGGC-
CCATTGTCG-3′. LCK-CRE mice were used as wild-type controls.
For reverse transcription quantitative PCR (RT-qPCR) on thymocytes 
isolated from EXT1F/F/lck-cre, Notch1FF/lck-cre, Notch1F/F EXT1F/F/lck-
cre, and lck-cre control mice, the following primers were used: mEXT1, 
5′- GCCCTTTTGTTTTATTTTGG-3′ (forward) and 5′-TCTTGCCTT-
TGTAGATGCTC-3′ (reverse); mNotch1, 5′-GACACCTCTGGACAAC-
GCCT-3′ (forward) and 5′-CGTGCTCACAAGGGTTGGCAC-3′ 
(reverse); glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
5′-CCAGTATGACTCCACTCACG-3′ (forward) and 5′-GACTC-
CACGACATACTCAGC-3′ (reverse). All experiments were performed 
with mice in the C57BL/6 background. The protocol was approved by 
the University of Liege ethical committee (authorization #13-1586).
Mice cell preparation, in vitro T cell activation, 
and polarization
Single-cell suspensions from the spleen, lymph node, blood, and thy-
mus were obtained by mechanical disruption, straining over a 40-mm 
nylon mesh, and lysis of erythrocytes. For primary T cell activation, 
polarization, and cytokine detection of wild-type or k.o. mice, iso-
lated CD4+ T cells from the spleen and lymph nodes by negative 
magnetic separation (magnetic-activated cell sorting) using CD4+ 
T cell isolation kit (Miltenyi Biotech) were cultured at a density of 1 × 
106 cells/ml on a 96-well plate for 72 hours with biotinylated CD3 
and CD28 antibodies. Activation and polarization were performed 
using the T Cell Activation/Expansion Kit (Miltenyi Biotech), as 
described in the manufacturer’s instruction manual.
RNA extraction and RT-qPCR (human cell lines)
Total RNA was extracted using NucleoSpin RNA kit (Macherey- 
Nagel) according to the manufacturer’s instructions. Real-time qPCR 
was performed using LightCycler 480 SYBR Green I Master (Roche) 
and analyzed in triplicate on a LightCycler (Roche). The relative ex-
pression levels were calculated for each gene using the Ct method 
with GAPDH as an internal control. Primer sequences for qPCR are as 
follows: EXT1, 5′-GCTCTTGTCTCGCCCTTTTGT-3′ (forward) and 
5′-TGGTGCAAGCCATTCCTACC-3′ (reverse); EXT2, 5′-GATT-
GAAGAAATGCAGAGACAGG-3′ (forward) and 5′-TGGATAGATCCG-
GTCATTGATA-3′ (reverse); EXTL1, 5′-TGGGCACAGGAAGGTTAGTG-3′ 
(forward) and 5′-CTTGTGGAAAGACTGCTGCG-3′ (reverse); EXTL2, 
5′-ACTCGAGTGACAAGTGAGCC-3′ (forward) and 5′-TGTGG-
CAACACCTCATTGTG-3′ (reverse); EXTL3, 5′-CAAGAAGTCGTGT-
GCTGAGG-3′ (forward) and 5′-GCCAACAATCAGGCCATGTG-3′ 
(reverse); GAPDH, 5′-TTGCCATCAATGACCCCTTCA-3′ (forward) 
and 5′-CGCCCCACTTGATTTTGGA-3′ (reverse).
Bromodeoxyuridine proliferation assay
A total of 5 × 103 HeLa shCTRL and shEXT1 cells were seeded in a 
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was added to the culture medium according to the manufacturer’s 
instructions (BrdU Cell Proliferation Assay Kit, Cell Signaling), and 
cells were further incubated for 24, 48, and 72 hours. The absorbance 
value for each well was measured at 450 nm with a microplate reader 
TECAN Infinite 200 PRO.
Proliferation assay using the xCELLigence system
HeLa shCTRL and shEXT1 cells were resuspended in cell culture medi-
um and adjusted to 5000 cells per well. One hundred microliters of each cell 
suspension was added to the 100 l of medium-containing wells on E-Plate 
96. Cell index was monitored every 3 min for a period of up to 72 hours. 
The xCELLigence system was used according to instructions supplied 
by Roche Applied Science and ACEA Biosciences (44).
Subcutaneous xenograft studies
Jurkat cells expressing control luciferase (shLUC or LUC-GFP) and 
the corresponding shEXT1 or EXT1-LUC-GFP, respectively, were 
used. Briefly, 2 × 106 viable human cells were mixed with an equal 
volume BD Matrigel basement membrane matrix and injected into 
the flanks of 6-week-old sublethally irradiated female NOD-SCID 
mice. Cell growth and engraftment were monitored every 3 days 
(Caliper, PerkinElmer). Animals were given an intraperitoneal injec-
tion of d-luciferin (150 mg/kg; Promega) and were imaged in groups 
of up to three mice (for display purposes).
Transmission electron microscopy
HeLa; HEK293 and Jurkat shCTRL and shEXT1; and HeLa shEXT2, 
shEXTL1, shEXTL2, and shEXTL3 cells also activated naive CD4+ T cells 
from peripheral lymph organs (spleen and lymph nodes) of EXT1F/F; 
LCK-CRE and LCK-CRE mice that were fixed for 90 min at 4°C 
with 2.5% glutaraldehyde in Sörensen 0.1 M phosphate buffer (pH 7.4) 
and postfixed for 30 min with 2% osmium tetroxide. Following de-
hydration in graded ethanol, samples were embedded in Epon. Ultra-
thin sections obtained with a Reichert Ultracut S ultramicrotome were 
contrasted with uranyl acetate and lead citrate. The analysis was per-
formed with a JEOL JEM-1400 transmission electron microscope at 
80 kV and in a Tecnai Spirit T12 at 120 kV (Thermo Fisher Scientific, 
The Netherlands).
Immunohistochemistry
Immunohistochemical experiments were performed using a stan-
dard protocol previously described (45). In the present study, the 
antigen retrieval step was citrate (pH 6.0), and the following primary 
antibody used was anti-EXT1 (1:50; ab126305, Abcam). The rabbit 
EnVision kit (Dako) was used for the secondary reaction.
Flow cytometry, extracellular, and intracellular staining
Single-cell suspensions from the spleen, lymph node, blood, and 
thymus were prepared as described above. Cells were resuspended 
in phosphate-buffered saline (PBS) and stained with the following 
fluorochrome-conjugated monoclonal antibodies purchased from BD 
Biosciences: anti-mouse CD4–PE (phycoerythrin) CF594 (RM4-5), 
anti- mouse CD8a-APC (allophycocyanin)-H7 (53-6.7), anti-mouse 
CD45R/B220-V500 (RA3-6B2), and anti-mouse CD25-BB515 (PC61) 
for 30 min at 4°C. Cells were washed twice and analyzed by fluorescence- 
activated cell sorting (FACS). Extracellular stains were performed in 
PBS supplemented with 0.5% bovine serum albumin and 10% 24G.2 
blocking antibody. After polarization, cells were fixed and permeabi-
lized using Foxp3/transcription factor intracellular staining buffer set 
(eBioscience). The following conjugated monoclonal antibodies were 
used: anti-mouse IL-17A (interleukin-17A)–efluor450 (eBio17B7), 
anti-mouse IFN-–APC (XMG1.2), and anti-mouse IL-4–APC (11B11). 
The carboxyfluorescein diacetate succinimidyl ester dye was used to 
label the dead cells. To quantify HS at the cell surface, 1 × 106 cells are 
incubated in 100 l of PBS for 20 min at 37°C. Cells are then washed 
in PBS and incubated with mouse anti-HS (10E4) for 30 min at 4°C, 
washed with PBS, and stained with Alexa Fluor 647 secondary anti- 
mouse antibody for 30 min at 4°C. Cells are analyzed immediately by 
flow cytometry on a BD LSRFortessa flow cytometer (BD Biosciences).
Plasmids
HA-SEC13 pRK5 (Addgene #46332), mEmerald-Sec61b-C1 (Addgene 
#90992), pEGFP-SEC16b (Addgene #66607), pEGFP-SEC23A (Addgene 
#66609), Str-KDEL-TNF-SBP-mCherry (Addgene #65279), and b4GALT1- 
pmTirquoise2-N1 (Addgene #36205) constructs were obtained from 
Addgene. ts045-VSVG-GFP (Addgene #11912) is a gift from F. Heyd 
(Freie Universität Berlin, Berlin, Germany). EXT1-YFP and Flag-EXT1 
were previously described (17). Additional cloning vectors used here 
are as follows: pCSCherryDEST (Addgene #13075), mEmerald-C1 
(Addgene #53975), and pSYFP2-C1 (Addgene #22878) or pCS2 EIF 
ires GFP. The lentiviral constructs used are as follows: shCTRL (anti– 
enhanced GFP, SHC005, Sigma-Aldrich) or pLV U6 shRNA NT PGK 
GFP-T2A-Neo, and targeting EXT1 (sh438, TRCN0000039993; sh442, 
TRCN0000039997; Sigma-Aldrich). The shRNAs targeting EXT2, 
EXTL1, EXTL2, and EXTL3 were designed using the VectorBuilder on-
line platform and cloned into the lentiviral vector pLV-PURO-U6. 
The target sequences are listed as follows: EXT2, 5′-AGCGTACTTC-
CAGTCAATTAAC-3′ or 5′-CCATTGATGATATCATTA-3′; EXTL1, 
5′-TGATCGCTTCTACCCATATAG-3′ or 5′-ATACCACTCTG-
GAGGTTATTC-3′; EXTL2, 5′-CTCTACTTCATCAGGTATCTA-3′ 
or 5′-GATTCGAGTGCTTCGATTATC-3′; EXTL3, 5′-CCGTACT-
GAGAAGAACAGTTT-3′ or 5′-TTGCCATTCAAGGCTTATTTA-3′. 
mCherry-RTN4a, mChery-ATL1, and Lnp1-mCherry lentiviral constructs 
were a gift from T. Rapoport (Department of Cell Biology, Harvard Med-
ical School, MA, USA). LV-PA-GFP-KDEL is a gift from V. C. Jones (Uni-
versity of Central Lancashire, Preston, UK), and Lenti-ATL3-GFP is a 
gift from V. Timmerman (University of Antwerp, Antwerp, Belgium). 
Lentivirus production and instructions on its use were provided by Vi-
ral Vectors core facility (Viral Vectors Platform, University of Liege).
Mammalian cell lines generation and culture
HeLa, HEK293, Jurkat, and Cos7 cells were cultured as previously 
described (17). All stable cell lines were generated by lentiviral trans-
duction. Briefly, HEK293T Lenti-x 1B4 cells (Clontech Lenti-x HEK293T 
cells) were transfected with calcium phosphate with three plasmids: 
the vector of interest, pVSV-G (PT3343-5, Clontech), and psPAX2 
(Addgene #12260). The supernatants containing the second-generation 
viral vectors were harvested and concentrated by ultracentrifuga-
tion. The cells were transduced with the viral vector of interest with 
a multiplicity of infection of 50. After 72 hours, the cells were selected for 
puromycin (InvivoGen) for 3 to 4 days. For fluorescence protein– 
tagged constructs, positive cells were sorted by flow cytometry.
DNA-siRNA transfection
DNA was transfected into HeLa and Cos7 with polyethyleneimine 
(PEI 25K, Polysciences), as previously described (17). For siRNA trans-
fection, Cos7 and HeLa cells were transfected at 40 to 50% conflu-
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according to the manufacturer’s instructions (ProFection Mamma-
lian Transfection kit, Promega). The following siRNA duplexes were 
purchased from Eurogentec (Belgium): siEXT1(1), 5′- GGAUCAU-
CCCAGGACAGGA-3′; siEXT1(2), 5′-GGAUUCCAGCGUGCA-
CAUU-3′; siCTRL, 5′-GGCUGCUUCUAUGAUUAUGtt-3′.
Calcium flux detection assay
A total of 2 × 105 Cos7 cells were washed twice and processed for im-
munofluorescence. Fluo-4, acetoxymethyl (AM) loading solution was 
added on the cells according to the manufacturer’s instructions (Fluo-4 
Calcium Imaging Kit, Thermo Fisher Scientific). Images were acquired 
using a Leica TCS SP5 confocal microscope and the 63× oil objective; 
the analysis was performed in ImageJ software.
Preparation of microsomes from cultured cells
HeLa cells expressing FLAG-EXT1 or HeLa shCTRL and shEXT1 
(2 × 108) were harvested and washed with PBS and with a hypotonic 
extraction buffer [10 mM Hepes (pH 7.8), with 1 mM EGTA and 
25 mM potassium chloride] supplemented with a protease inhibitors 
cocktail. Cells were resuspended in an isotonic extraction buffer [10 mM 
Hepes (pH 7.8), with 0.25  M sucrose, 1 mM EGTA, and 25 mM 
potassium chloride] supplemented with a protease inhibitors cock-
tail and homogenized with 10 strokes using a Dounce homogenizer. 
The suspension was centrifuged at 1000g for 10  min at 4°C. The 
supernatant was centrifuged at 12,000g for 15 min at 4°C. The fol-
lowing supernatant fraction, which is the postmitochondrial frac-
tion (PMF), is the source for microsomes. The PMF was centrifuged 
for 60 min at 100,000g at 4°C. The pellet was resuspended in isoton-
ic extraction buffer supplemented with a protease inhibitor cocktail 
and stored at −80°C. Isolated membranes were boiled for 5 min in 
2× SDS loading buffer. Then, solubilized samples were separated on 
SDS–polyacrylamide gel electrophoresis (PAGE) and analyzed by 
Western blotting.
Western blotting and antibodies
Cells were lysed in immunoprecipitation low-salt buffer [25 mM 
tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol, 
cOmplete Protease Inhibitor (Roche), and Halt Phosphatase Inhib-
itors (Thermo Fisher Scientific)]. SDS-PAGE and Western blotting 
were performed using standard protocols. The following primary anti-
bodies were used: mouse anti-Calnexin (1:2000; Abcam), rabbit anti- 
EXT1 (1:500; Prestige Antibodies, Sigma-Aldrich), mouse anti-NogoA 
(Santa Cruz Biotechnology), rabbit anti-FLAG (1:4000; Sigma-Aldrich), 
mouse anti-FLAG (1:4000; Sigma-Aldrich), goat anti-actin (1:2000; 
Santa Cruz Biotechnology), and rabbit-anti-HSP70 (1:3000; Santa Cruz 
Biotechnology). Dad1, STT3b, STT3a, Sec61A, Trap-, TRAP-, SEC62, 
and SEC63 rabbit antibodies were a gift from R. Zimmermann (Medical 
Biochemistry and Molecular Biology, Saarland University, Homburg, 
Germany). The following conjugated secondary antibodies were used: 
mouse anti–horseradish peroxidase (HRP) (1:5000; Santa Cruz Bio-
technology), rabbit anti-HRP (1:5000; Santa Cruz Biotechnology), 
and anti- goat (1:5000; Santa Cruz Biotechnology).
N-glycans and O-glycans profiling
Microsomes were isolated as described above, and glycans profil-
ing was performed by Creative Proteomics (NY, USA). Briefly, for 
the preparation of glycans, ~250 g of lyophilized trypsin- and 
peptide:N-glycosidase F (PNGase F)–digested protein samples were 
used in a permethylation reaction. Lyophilized eluted fraction was 
used for MS analysis. MS data were acquired on a Bruker UltraFlex II 
MALDI-TOF mass spectrometer instrument. The positive reflective 
mode was used, and data were recorded between 500 and 6000 mass/
charge ratio (m/z) for N-glycans and between 0 and 5000 m/z for 
O-glycans. For each MS N- and O-glycan profiles, the aggregation of 
20,000 laser shots or more was considered for data extraction. Mass 
signals of a signal/noise ratio of at least 2 were considered, and only 
MS signals matching an N- and O-glycan composition were consid-
ered for further analysis and annotated. Subsequent MS post–data 
acquisition analysis was made using mMass (46).
Glycosyltransferase assay
Glycosyltransferase activity of microsomes from HeLa shCTRL and 
shEXT1 was determined with the Glycosyltransferase Activity Kit 
(R&D Systems). A glycosyltransferase reaction was carried out in 
50 l of reaction buffer in a 96-well plate at room temperature for 
20 min, according to the manufacturer’s instructions. The absorbance 
value for each well was measured at 620 nm with a microplate read-
er Tecan Infinite 200 PRO.
Metabolomics profiling
For metabolite quantification, HEK293 shCTRL and shEXT1 cells 
were seeded in triplicate (n = 3) in six-well plates with Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS). After 24 hours, the medium was removed and re-
placed with fresh medium containing a stable isotopic tracer 13C-glucose. 
For one well per condition, the medium was replaced with 12C-glucose. 
Upon reaching 70% confluency, the supernatant was stored at −80°C, 
cells were washed twice with PBS and harvested, and the cell pellet 
was stored at −80°C until liquid chromatography–MS (LC-MS) iden-
tification of metabolites at the University of Leuven metabolomics 
core facility.
Lipidomics
Lipidomics analysis was performed in the Lipidomics Core Facility 
of the University of Leuven, Laboratory of Lipid Metabolism. Briefly, 
20 g of protein or ER microsomes diluted in 700 l of water was 
mixed with 800 l of 1 N of HCl:CH3OH (1:8; v/v) and 900 l of 
CHCl3, in the presence of antioxidant 2,6-di-tert-butyl-4-methylphenol 
(200 g/ml; Sigma-Aldrich). Three microliters of SPLASH LIPIDOMIX 
Mass Spec Standard (#330707, Avanti Polar Lipids) was spiked into 
this mixture, and the samples were vortexed and centrifuged at 
4000g for 10 min. Lipid species were analyzed by hydrophilic inter-
action LC electrospray ionization MS/MS on a Nexera X2 ultrahigh- 
performance LC (UHPLC) system (Shimadzu) coupled with a hybrid 
triple quadrupole/linear ion trap mass spectrometer (6500+ QTRAP 
system, AB SCIEX). Chromatographic separation was performed on 
a XBridge amide column (150 mm by 4.6 mm, 3.5 m; Waters) main-
tained at 35°C using mobile phase A [1 mM ammonium acetate in 
water:acetonitrile, 5:95 (v/v)] and mobile phase B [1 mM ammonium 
acetate in water:acetonitrile, 50:50 (v/v)] using the gradient (0 to 
6 min, 0% B ➔ 6% B; 6 to 10 min, 6% B ➔ 25% B; 10 to 11 min, 
25% B ➔ 98% B; 11 to 13 min, 98% B ➔ 100% B; 13 to 19 min, 100% 
B; 19 to 24 min, 0% B) at a flow rate of 0.7 ml/min, which was in-
creased to 1.5 ml/min from 13 min onward. Lipid quantification 
was performed by scheduled multiple reaction monitoring (MRM), 
the transitions being based on the generation of neutral losses or 
typical fragment ions during collision-induced dissociation in MS/MS. 
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dihydroceramides (DCER), hexosylceramides (HCER), and lactosyl-
ceramides (LCER) were measured in positive ion mode with MRM 
transitions based on the generation of fragment ions of m/z of 184.1, 
369.4, 264.4, 266.4, 264.4, and 266.4, respectively. Triacylglycerides 
(TAG), diacylglycerides (DAG), and monoacylglycerides (MAG) were 
measured in positive ion mode with MRM transitions based on the 
neutral loss of each of the fatty acyl moieties. Phosphatidylcholine (PC), 
lysophosphatidylcholine (LPC), phosphatidylethanolamine (PE), 
lysophosphatidylethanolamine (LPE), phosphatidylglycerol 
(PG), lysophosphatidylglycerol (LPG), phosphatidylinositol (PI), 
lysophosphatidylinositol (LPI), phosphatidylserine (PS), and LPS 
were measured in negative ion mode with MRM transitions based 
on the neutral loss of each of the fatty acyl moieties.
Immunofluorescence and confocal, SR microscopy
A total of 3 × 104 Cos7 and 5 × 104 HeLa cells were grown on 18-mm 
round glass coverslips and transfected with 500 ng of DNA per well. 
For immunostaining, the cells were washed with PBS (pH 7.4) and 
fixed with 4% paraformaldehyde in PBS for 15 min at room tempera-
ture. Cells were permeabilized with 0.5% Triton X-100 for 10 min 
and incubated with blocking solution (0.025% Tween 20 and 10% 
FBS) for 30 min. Primary antibody staining was performed over-
night at 4°C in 5% blocking solution: mouse anti–-catenin (1:1000; 
RRID:AB_626807), mouse anti-Calnexin (1:500; RRID:AB_2069009), 
rabbit anti-EXT1 (1:100; RRID:AB_10963838), mouse anti-HS (10E4; 
RRID:AB_10013601), rabbit anti-GM130 (1:3200; RRID:AB_2797933), 
mouse anti-PDIA3 (1:1000; RRID:AB_2665750), and mouse anti- 
SEC31 (1:500; RRID:AB_399716). Goat anti-rabbit, donkey anti-rabbit, 
or goat anti-mouse secondary antibodies labeled with Alexa Fluor 
488 or Texas Red (Thermo Fisher Scientific) and anti-mouse STAR-
Red (Abberior) were used at a 1:2000 dilution for 1 hour. Cells were 
stained with 4′,6-diamidino-2-phenylindole (Thermo Fisher Scien-
tific) when needed for 5 min at room temperature and were mounted 
with ProLong Antifade Mountants (Thermo Fisher Scientific). Slides 
were analyzed by confocal microscopy with a Leica TCS SP8 micro-
scope using the 100× oil objective. Images were taken at 2068 by 
2068 pixel resolution and deconvoluted with Huygens Professional 
software. SYFP2-EXT1 was analyzed by STED microscopy with a 
Leica SP8 STED 592-nm laser. Images were taken at 2068 by 2068 
pixel resolution and deconvoluted with Huygens Professional software. 
SEC31 was analyzed with a Stedycon STED 775-nm laser. mEmerald- 
EXT1 was analyzed by SR SIM. SIM imaging was performed at the 
Cell Imaging and Cytometry Core facility (Turku University) using 
a DeltaVision OMX SR V4 microscope using a 60×/1.42 Olympus 
Plan Apo N SIM objective and scientific complementary metal–oxide–
semiconductor (sCMOS) cameras (Applied Precision), with 2560 by 
2160 pixel resolution. The SIM image reconstruction was performed 
with DeltaVision softWoRx 7.0 software. For live imaging of Cos7 cells 
expressing mCherry-ATL1 or Lnp1-mCherry, 3 × 104 cells were plated 
and imaged at 37°C and 5% CO2 in a thermostat- controlled chamber 
on a Zeiss LSM800 AiryScan Elyra S1 SR confocal microscope using 
the 63× oil objective at 1 frame/100 ms for 5 s. Further analysis was 
performed in ImageJ software.
Photoactivatable GFP imaging
A total of 3 × 104 Cos7 cells expressing PA-GFP-KDEL were plated, 
and live imaging was performed at 37°C and 5% CO2 in a thermostat- 
controlled chamber on a Zeiss LSM800 AiryScan Elyra S1 SR con-
focal microscope using the 100× oil objective. PA-GFP-KDEL was 
activated at a perinuclear ER region using the 405-nm laser at 100%, 
after which the cell was imaged at 1 frame/500 ms for 90 s using the 
488-nm laser. Fluorescence intensities were measured using ImageJ 
software, and data analysis and curve fitting were performed in 
GraphPad Prism 8 (GraphPad Software). To avoid intercell variability, 
the activation site was at the perinuclear area of cells with the same ER 
density. The integrated fluorescence intensity of each region of in-
terest (ROI) at fixed distances (8, 12, and 16 m) from the activation 
region was measured in ImageJ. Normalization of raw values was per-
formed by defining the initial fluorescence to 0 and the maximum flu-
orescence to 1 for each ROI. Image analysis was performed in ImageJ.
Affinity purification and MS
Solubilization buffer (2×) [3.5% digitonin, 100 mM Hepes (pH 7.5), 
800 mM KOAc, 20 mM MgOAc2, and 2 mM dithiothreitol] was 
mixed in a ratio 1:1 with the microsomal fraction and incubated 
10 min on ice. Equilibrated agarose beads M2-FLAG (Sigma-Aldrich) 
were added in the microsomal fraction (15 l of beads per half of a 
10-cm cell culture dish), and rotation was performed overnight at 
4°C. Beads were washed three times for 15 min with glycine of 50 mM 
(pH 3.0) for protein elution. The supernatant was supplemented 
with tris-HCl (pH 8.0). Eluted proteins were then subjected to tryp-
sin digestion and identified by MS.
For glycopeptide identification, the resulting MS/MS data were 
processed using Byonic 3.5 (Protein Metrics) search engine within 
the Proteome Discoverer 2.3 against a human database obtained 
from UniProt; the glycan database was set to “N-glycan 182 human 
no multiple fucose or O-glycan 70 human.” Trypsin was specified as 
cleavage enzyme, allowing up to two missed cleavages, five modifi-
cations per peptide, and up to seven charges. Mass error was set to 
10 parts per million (ppm) for precursor ions and 20 ppm for frag-
ment ions. Oxidation on Met, carbamidomethyl (+57.021 Da) was 
considered as variable modifications on Cys. Glycopeptides with a 
Byoinic score of ≥300 and with a Log Prob of ≥4.0 were retained, 
and their identification was manually validated.
SILAC labeling
HeLa cells (shCTRL and shEXT1) were cultured for at least five cell 
doublings in either isotopically light or heavy SILAC DMEM ob-
tained from Thermo Fisher Scientific (catalog number A33969) con-
taining 10% FBS and streptomycin (50 g/ml) and penicillin (50 U/ml) 
(Lonza). For the heavy SILAC medium, 50 mg of 13C6 l-lysine–2HCl 
(heavy) and 50 mg of l-arginine–HCl were added. In light SILAC 
medium, 50 mg of l-lysine–2HCl (light) and 50 mg of l-arginine–HCl 
were added. A total of 2 × 105 cells were adapted to grow in DMEM. The 
cell pellet was suspended in 150 l of modified radioimmunopre-
cipitation assay (RIPA) buffer and sonicated, followed by incuba-
tion at 60°C for 15 min. Samples were clarified by centrifugation; each 
replicate was pooled and quantified by Qubit (Invitrogen): 20 g of the 
sample was separated on a 4 to 12% bis-tris Novex minigel (Invitrogen) 
using the Mops buffer system. The gel was stained with Coomassie, 
and gel bands were excised at 50 and 100 kDa. Gel pieces were pro-
cessed using a robot (ProGest, DigiLab). They were washed with 25 mM 
ammonium bicarbonate followed by acetonitrile, reduced with 10 mM 
dithiothreitol at 60°C followed by alkylation with 50 mM iodoacet-
amide at room temperature, and digested with trypsin at 37°C for 
4 hours. Last, they were quenched with formic acid, and the superna-
tant was analyzed directly without further processing. For the SILAC 
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were pooled 1:1, and 20 g was separated on a 4 to 12% bis-tris Novex 
minigel (Invitrogen) using the Mops buffer system. The gel was stained 
with Coomassie, and the lanes were excised into 40 equal segments 
using a grid. For MS, the gel digests were analyzed by nano–LC-MS/
MS with a Waters NanoAcquity HPLC system interfaced to a Ther-
mo Fisher Scientific Q Exactive. Peptides were loaded on a trapping 
column and eluted over a 75-m analytical column at 350 nl/min. Both 
columns were packed with Luna C18 resin (Phenomenex). Data were 
processed through the MaxQuant software 1.5.3.0 (www.maxquant.
org), which served several functions such as the recalibration of MS 
data, the filtering of database search results at the 1% protein and pep-
tide false discovery rate, the calculation of SILAC heavy/light ratios, 
and data normalization.
Rush assay
An adaptation of the published assay (33) was used. HeLa cells were 
transfected with Str-KDEL-TNF-SBP-mCherry construct as described 
above, and 24 hours after transfection, mCherry-positive cells were 
sorted. A total of 5 × 104 cells were cultured on 35-mm imaging dish. 
The day after, cells were transferred at 37°C in a thermostat-controlled 
chamber. At time point zero, the medium was removed and replaced 
with medium containing d-biotin (Sigma-Aldrich) at 40 M concen-
tration. The time-lapse acquisition was made using a Zeiss LSM800 
AiryScan Elyra S1 SR confocal microscope. Images were acquired 
using a 63× oil objective. For each time point, the integrated inten-
sity of an ROI was measured. The integrated intensity of an identical- 
size ROI corresponding to background was measured and subtracted 
from the values of the integrated intensity for each time point. The 
values were then normalized to the maximum value. These quanti-
fications were performed using the Zeiss Black software.
Export assay
A total of 3 × 104 Cos7 cells were cultured on 35-mm imaging dish 
and transfected with the ts045-VSVG-GFP reporter construct and 
immediately incubated at 40°C overnight to retain the reporter pro-
tein in the ER. After the addition of cycloheximide, cells were trans-
ferred in a thermostat-controlled chamber at 40°C. The temperature 
was shifted to 32°C, and cells were processed for immunofluorescence 
at t = 0, t = 45, and t = 90 min and stained with mouse anti–-catenin 
antibody as described above. The acquisition was made using a Zeiss 
LSM800 AiryScan Elyra S1 SR confocal microscope. Images were 
acquired using a 40× oil objective.
Image analysis
For colocalization analysis, the average Pearson’s correlation coeffi-
cient test was performed with the plugin Colocalization Threshold 
in ImageJ software. To track the displacement of main junctions 
during successive frames, the dynamic features of the cell were re-
trieved from the time lapses of Cos7 cells expressing mCherry-ATL1 
or Lnp1-mCherry with the following image processing procedure. 
Images were preprocessed to uniformize the intensities. Then, each 
image was binarized and skeletonized using MATLAB 2016a. The 
skeleton was labeled using the AnalyzeSkeleton plugin from ImageJ. From 
this process, each pixel of the skeleton was classified according to its 
neighborhood, leading to three-pixel classes: end point, junctions, 
and tubules. To reflect the structure of the ER, the ratio of the junc-
tions over the tubules was computed for mCherry-ATL1 and Lnp1- 
mCherry proteins. The dynamics of the ER was assessed by the main 
junction displacement during a time lapse. To achieve the tracking 
of the displacement, the junctions larger than three pixels were kept 
segmented. Then, the segmented objects were multiplied by the initial 
image intensity to consider the initial light intensity. Last, a Gaussian 
blur was applied to these objects. The tracking of the bright spot was 
achieved using a single-particle tracking algorithm, the “simple LAP 
tracker” available in ImageJ plugin TrackMate. The parameters were 
set following the recommendations for Brownian motion–like move-
ments, i.e., a max linking distance of 7 pixels, a max closing distance 
of 10 pixels, and a max frame gap of 3 pixels. From the results of 
TrackMate, only the tracks longer than 10 frames were kept to reduce 
the noise. Last, using all velocity vectors measured, a cumulative ve-
locity distribution was computed. Furthermore, a diffusion coefficient 
based on instantaneous velocity was computed using the MATLAB 
as described previously (32).
In the AnalyzER software (47), original images were imported, 
and the ROIs were segmented using Otsu’s method. Cisternae are 
identified using an image opening function and active contour re-
finement. The tubular network is enhanced using phase congruency, 
and the resulting enhanced network is skeletonized to produce a 
single-pixel-wide skeleton running along each tubule. Regions fully 
enclosed by the skeletonized tubular network and the cisternae are 
defined as polygonal regions, and features such as area, circularity, 
and elongations are extracted.
SAFE analysis
We used the SAFE software (v1.5) to determine and visualize signif-
icant functional modules (i) in the network of EXT1 partners and 
their first-order neighbors excerpted from the STRING database 
with confidence over 0.95 and (ii) in the network of genes whose 
expressions are significantly regulated by EXT1 k.d. obtained from 
the STRING database with confidence over 0.9. The network lay-
outs were generated with Cytoscape (v3.4.0) using the edge-weighted 
spring-embedded layout. Gene ontology (GO) terms for each gene 
were extracted from FuncAssociate (v3; GO updated on February 2018). 
The SAFE analysis was run with the default option.
RNA sequencing
RNA sequencing analysis was previously described and is deposited 
as GSE138030.
Model generation and FBA
Model generation and in silico FBA were performed using the COBRA 
toolbox V3.0 in the MATLAB 2018a environment with an interface 
to IBM Cplex and GNU Linear Programming Kit (GLPK) solvers 
provided in the COBRA toolbox. Linear programing problems were 
solved on a macOS Sierra version 10.12.6. To generate the control 
and EXT1 k.d.–specific models, the gene expression mRNA data for 
samples of control EXT1 k.d. cells (RNA sequencing) were integrated 
with the COBRA human model, RECON2. The integration step uses 
the GIMME (gene inactivity moderated by metabolism and expres-
sion) algorithm, available in the COBRA toolbox. Because GIMME 
requires binary entries for the indication of the presence or absence 
of genes, we used a gene expression threshold value equals to the 
first quartile RPKM (reads per kilobase of transcript per million) for 
genes in control and EXT1 k.d. cells. GIMME only integrates reac-
tions associated with active genes, leaving those associated with the 
lowly expressed genes inactive. Therefore, genes with expression val-
ues below the threshold were given the value of 0 (inactive), and 
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value of 1 (active). FBA calculates the flow of metabolites through a 
metabolic network, thereby predicting the flux of each reaction con-
tributing to an optimized biological objective function such as growth 
rate. Simulating growth rate requires the inclusion of a reaction that 
represents the production of biomass, which corresponds to the rate 
at which metabolic precursors are converted into biomass compo-
nents, such as lipids, nucleic acids, and proteins. For both models 
generated after the integration step, we used the biomass objective 
function as defined in the RECON2 model to obtain the FBA solu-
tion using the COBRA Toolbox command, optimizeCbModel. After 
identification of the objective function in the model, the entries to 
the command optimizeCbModel are as follows: the model and the 
required optimization of the objective function (maximum produc-
tion). The command output is the FBA solution, which includes the 
value of the maximum production rate of the biomass and a column 
vector for the conversion rate value (reaction fluxes) of each metab-
olite accounted for in the model.
Statistical analysis
Graph values are represented as means ± SD of the mean calculated 
on at least three independent experiments/samples. The analyses 
were performed in Prism 8 (GraphPad Software). The statistical sig-
nificance between means was determined using one-way analysis of 
variance (ANOVA), followed by two-tailed, unpaired Student’s 
t test. P value thresholds are depicted as follows: *P < 0.05, **P < 0.01, 
***P < 0.001, and ****P < 0.0001; n.s. indicates not significant. Sig-
nificance for PA-GFP-KDEL was performed using two-way ANOVA, 
followed by Sidak’s multiple comparisons test. Significance for Rush 
assay was performed using the two-stage linear step-up procedure 
of Benjamini, Krieger, and Yekutieli, with Q = 1%. Each time point 
was analyzed individually, without assuming a consistent SD.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/19/eabe8349/DC1
View/request a protocol for this paper from Bio-protocol.
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